Advance Search

Screening of cellular immunity of T cells in endometrial cancer patients via measurement of interferon gamma, interleukin 22, interleukin 17, interleukin 13, interleukin 10, interleukin 4, interleukin 2, and tumor necrosis factor alpha cytokines

Salar Saadi Dizayee
Department of Basic Sciences, College of Nursing, Hawler Medical University, Erbil, Kurdistan Region, Iraq
Zahra Abdulqader Amin
Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq
Keywords:
Copyright and Licensing:

Copyright (c) 2026 Salar Saadi Dizayee, Zahra Abdulqader Amin (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Background and objective: Endometrial cancer (EC) is considered the sixth most prevalent cancer among women worldwide, with over 400,000 new cases annually, and both its incidence and mortality rates are rising. This study attempted to examine the concentrations of interleukins (IL-2, IL-4, IL-10, IL-13, IL-17, IL-22), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ) in Kurdish women diagnosed with endometrial cancer.

Methods: Seventy patients were included in the study, from which random samples were selected for testing by ELISA multiplex enzyme immunoassay. Serum was separated from the patients' peripheral blood.

Results: The findings revealed a significant (p <0.05) increase in mean concentration of IFN-γ (55±0.2 pg/mL), IL-2 (122±0.33 pg/mL), TNF-α (18.14±9.06 pg/mL), IL-17 (3.06±1.49 pg/mL), IL-22 (10.34±2.34 pg/mL), and IL-4 (9.75±11.35 pg/mL) in patients diagnosed with endometrial cancer compared with their respective healthy individuals, whereas no significant difference was found in the level of IL-10 (3.02±1 pg/mL) in endometrial cancer patients compared with healthy individuals (3.00±0.3 pg/mL). Finally, IL-13 levels showed a significant decrease in EC patients (0.99±0.11 pg/mL) compared with healthy individuals (2.1±0.2 pg/mL).

Conclusion: The study demonstrates a significant elevation of pro-inflammatory cytokines (IFN-γ, IL-2, TNF-α, IL-17, IL-22, and IL-4) and a marked reduction of IL-13 in endometrial cancer patients, suggesting their involvement in tumorigenesis and local immune dysregulation. IL-10 levels remained unchanged, indicating complex immune dynamics.

PDF
PDF

Metrics

Metrics Loading ...

References

  1. Jiang S, Ye M, Wan J, Ye Q, Qiu S, Yang Y, et al. Significance of gelsolin superfamily genes in diagnosis, prognosis and immune microenvironment regulation for endometrial cancer. Cancer Med. 2025;14(4):e70584. https://doi.org/10.1002/cam4.70584
  2. D'Alterio C, Rea G, Napolitano M, Coppola E, Spina A, Russo D, et al. Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin+paclitaxel/avelumab (MITO-END3 trial). Cancer Immunol Immunother. 2025;74(6):1-12. https://doi.org/10.1007/s00262-025-04021-3
  3. Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med. 2020;383(21):2053-64. https://doi.org/10.1056/NEJMra1514010
  4. Chang C-W, Yang S-T, Liu C-H, Chang W-H, Lee W-L, Wang P-H. Endometrial cancer: part II. Multimodality treatment of uterine high-grade serous carcinoma (clinical course I). Taiwan J Obstet Gynecol. 2025;64(3):413-24. https://doi.org/10.1016/j.tjog.2024.03.034
  5. Kang Y-J, Cho HJ, Lee Y, Park A, Kim MJ, Jeung IC, et al. IL-17A and Th17 cells contribute to endometrial cell survival by inhibiting apoptosis and NK cell mediated cytotoxicity of endometrial cells via ERK1/2 pathway. Immune Netw. 2023;23(2):e14. https://doi.org/10.4110/in.2023.23.e14
  6. Zang Y, Li H, Liu S, Zhao R, Zhang K, Zang Y, et al. The roles and clinical applications of interleukins in endometrial carcinoma. Front Oncol. 2022;12:1001693. https://doi.org/10.3389/fonc.2022.1001693
  7. Cai Y, Zhai J, Wu Y, Chen R, Tian X. The role of IL-2, IL-4, IL-10 and IFN-γ cytokines expression in the microenvironment of cervical intraepithelial neoplasia. Adv Reprod Sci. 2022;10(4):106-14. https://doi.org/10.4236/arsci.2022.104010
  8. Majidpoor J, Mortezaee K. Interleukin-2 therapy of cancer — clinical perspectives. Int Immunopharmacol. 2021;98:107836. https://doi.org/10.1016/j.intimp.2021.107836
  9. Zmarzly N, Januszyk S, Mieszczanski P, Czarniecka J, Bednarska-Czerwinska A, Boron D, et al. The influence of selected microRNAs on the expression profile of genes and proteins related to the tumor necrosis factor-alpha signaling pathways in endometrioid endometrial cancer. J Cancer Res Clin Oncol. 2023;149(12):9679-89. https://doi.org/10.1007/s00432-023-04863-3
  10. Wieder-Huszla S, Chudecka-Głaz A, Gutowska I, Karakiewicz B, Jurczak A. Effect of the treatment stage on the serum levels of selected cytokines and antioxidant enzymes in patients with tumors of the reproductive organs. Eur Rev Med Pharmacol Sci. 2023;27(7). http://dx.doi.org/10.26355/eurrev_202304_31946
  11. Nikseresht M, Shahrebabaki AM, Mohammad-Sadeghipour M, Hajizadeh MR, Zarei S, Hosseiniara R, et al. Comparison of serum levels of IL-10 and IL-11 and mRNA expression of IL-10, IL-11, COX-2, BCL6, and ZEB family in peripheral blood mononuclear cells (PBMC) of women with polycystic ovary syndrome and healthy individuals. J Reprod Immunol. 2024;164:104281. https://doi.org/10.1016/j.jri.2024.104281
  12. Nati ID, Malutan A, Ciortea R, Oancea M, Bucuri C, Roman M, et al. Exploring the influence of IL-8, IL-10, patient-reported pain, and physical activity on endometriosis severity. Diagnostics (Basel). 2024;14(16):1822. https://doi.org/10.3390/diagnostics14161822
  13. Oală IE, Mitranovici M-I, Chiorean DM, Irimia T, Crișan AI, Melinte IM, et al. Endometriosis and the role of pro-inflammatory and anti-inflammatory cytokines in pathophysiology: a narrative review of the literature. Diagnostics (Basel). 2024;14(3):312. https://doi.org/10.3390/diagnostics14030312
  14. Alspach E, Lussier DM, Schreiber RD. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 2019;11(3):a028480. https://doi.org/10.1101/cshperspect.a028480
  15. Liu C, Wang D, Huang X, Song Z, Ye L, Zhou G. The expression and clinical significance of cytokines Th1, Th2, and Th17 in ovarian cancer. Am J Med Sci. 2025;369(3):346-53. https://doi.org/10.1016/j.amjms.2024.08.029
  16. Wieser V, Abdel Azim S, Sprung S, Knoll K, Kögl J, Hackl H, et al. TNFα signalling predicts poor prognosis of patients with endometrial cancer. Carcinogenesis. 2020;41(8):1065-73. https://doi.org/10.1093/carcin/bgaa034
  17. Shi J-L, Zheng Z-M, Chen M, Shen H-H, Li M-Q, Shao J. IL-17: an important pathogenic factor in endometriosis. Int J Med Sci. 2022;19(4):769. https://doi.org/10.7150/ijms.71972
  18. Liu S, Zhao R, Zang Y, Huang P, Zhang Q, Fan X, et al. Interleukin-22 promotes endometrial carcinoma cell proliferation and cycle progression via ERK1/2 and p38 activation. Mol Cell Biochem. 2024:1-14. https://doi.org/10.1007/s11010-024-05179-7
  19. Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2021;10:1-17. https://doi.org/10.1186/s40164-021-00252-z
  20. Rallis KS, Corrigan AE, Dadah H, Stanislovas J, Zamani P, Makker S, et al. IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation — a comprehensive review. Future Oncol. 2022;18(29):3349-65. https://doi.org/10.2217/fon-2022-0063
How to Cite
Saadi Dizayee, S., & Abdulqader Amin, Z. (2026). Screening of cellular immunity of T cells in endometrial cancer patients via measurement of interferon gamma, interleukin 22, interleukin 17, interleukin 13, interleukin 10, interleukin 4, interleukin 2, and tumor necrosis factor alpha cytokines. Zanco Journal of Medical Sciences (ZJMS), 647–656. https://doi.org/10.15218/zjms.2026.045

Send mail to Author

Send Cancel